Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study

Bone Marrow Transplantation

Volumn 53, Issue 10, 2018, Pages 1328-1335

  Alsuliman, Tamim ^a,b   Kitel, Caroline ^a   Dulery, Rémy ^c   Guillaume, Thierry ^d   Larosa, Fabrice ^e   Cornillon, Jérôme ^f   Labussière Wallet, Helene ^g   Médiavilla, Clémence ^h   Belaiche, Stéphanie ^a   Delage, Jeremy ⁱ   Alain, Sophie ^j   Yakoub Agha, Ibrahim ^a,k  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Service d'Hématologie CH Boulogne Sur Mer   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f Service d'hématologie Adulte   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j UMR 1092   (France)

^k UNIVERSITÉ DE LILLE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET SODIUM; GANCICLOVIR; IMMUNOGLOBULIN G; STEROID; CYTOMEGALOVIRUS-SPECIFIC HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LACK OF DRUG EFFECT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT INFECTION; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REACTIVATION; AGED; ALLOGRAFT; CLINICAL TRIAL; CYTOMEGALOVIRUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY;

ADULT; AGED; ALLOGRAFTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 85045288886     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/s41409-018-0166-9     Document Type: Article

References (47)

1. Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M. et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant. 2012;18:289–94.S1083-8791(11)00303-X [pii] 10.1016/j.bbmt.2011.07.013
2. Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M. et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol. 2012;30:4533–40.10.1200/JCO.2012.44.3499
3. Depil S, Deconinck E, Milpied N, Sutton L, Witz F, Jouet JP. et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant. 2004;33:531–4.10.1038/sj.bmt.1704381 1704381 [pii]
4. Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S. et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32:3264–74.10.1200/JCO.2014.55.2018
5. Nguyen S, Chalandon Y, Lemarie C, Simon S, Masson D, Dhedin N. et al. [Haploidentical hematopoietic stem cell transplantation: guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer. 2016;103(11S):S229–S242.S0007-4551(16)30220-X [pii] 10.1016/j.bulcan.2016.09.007
6. Bay JO, Peffault de Latour R, Bruno B, Coiteux V, Guillaume T, Hicheri Y. et al. [Diagnosis and treatment of CMV and EBV reactivation as well as post-transplant lymphoproliferative disorders following allogeneic stem cell transplantation: an SFGM-TC report]. Pathol Biol. 2013;61:152–4.S0369-8114(13)00112-0 283[pii] 10.1016/j.patbio.2013.07.003
7. Bordon V, Bravo S, Van Renterghem L, de Moerloose B, Benoit Y, Laureys G. et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transplant Infect Dis. 2008;10:19–23.10.1111/j.1399-3062.2007.00242.x
8. Choufi B, Thiant S, Trauet J, Cliquennois M, Cherrel M, Boulanger F. et al. [The impact of donor naive and memory T cell subsets on patient outcome following allogeneic stem cell transplantation: relationship between infused donor CD4+/CCR7+T cell subsets and acute graft-versus-host disease]. Pathol Biol. 2014;62:123–8.S0369-8114(14)00060-1 [pii] 10.1016/j.patbio.2014.02.013
9. Choufi B, Trauet J, Thiant S, Labalette M, Yakoub-Agha I. Donor-derived CD4(+)/CCR7(+) T-cell partial selective depletion does not alter acquired anti-infective immunity. Bone Marrow Transplant. 2014;49:611–5.bmt20146 [pii] 10.1038/bmt.2014.6
10. Yakoub-Agha I, Saule P, Magro L, Cracco P, Duhamel A, Coiteux V. et al. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+T cells on relapse. Biol Blood Marrow Transplant. 2009;15:496–504.S1083-8791(08)00588-0 [pii] 10.1016/j.bbmt.2008.11.038
11. Yakoub-Agha I, Saule P, Depil S, Grutzmacher C, Boulanger F, Magro L. et al. Comparative analysis of naive and memory CD4+and CD8+T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics. Exp Hematol. 2007;35:861–71.S0301-472X(07)00187-7 [pii] 10.1016/j.exphem.2007.03.006
12. de la Cámara R. CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016; 8. doi: https://doi.org/10.4084/mjhid.2016.031
13. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25:151–69. 10.1016/j.hoc.2010.11.011
14. van der Beek MT, Marijt EW, Vossen AC, van der Blij-de Brouwer CS, Wolterbeek R, Halkes CJ. et al. Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients. Antivir Ther. 2012;17:45–51.10.3851/imp1899
15. Boeckh M, Zaia JA, Jung D, Skettino S, Chauncey TR, Bowden RA. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant. 1998;4:13–19
16. Schulz U, Solidoro P, Muller V, Szabo A, Gottlieb J, Wilkens H. et al. CMV Immunoglobulins for the treatment of CMV infections in thoracic transplant recipients. Transplantation. 2016;100:S5–10.10.1097/tp.0000000000001097
17. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–9. 10.1182/blood-2008-10-143560
18. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol. 2008;18:233–46.10.1002/rmv.574
19. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL, Viral DNA. polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis. 2003;188:32–39.10.1086/375743
20. Hertenstein B, Hampl W, Bunjes D, Wiesneth M, Duncker C, Koszinowski U. et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant. 1995;15:387–93
21. Messori A, Rampazzo R, Scroccaro G, Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. 1994;13:163–7
22. Adler SP, Nigro G. Findings and conclusions from CMV hyperimmune globulin treatment trials. J Clin Virol. 2009;46:S54–57.10.1016/j.jcv.2009.08.017
23. Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM. et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 2010;30:554–61.10.1592/phco.30.6.554
24. Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N. et al. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica. 1998;83:132–7
25. Belaiche S, Yafour N, Balcaen S, Beguin Y, Borel C, Bruno B. et al. [Utilisation of immunosuppressants in the prevention of a graft versus host reaction: report by the SFGM-TC]. Pathol Biol. 2014;62:197–203.S0369-3788114(14)00070-4 [pii] 10.1016/j.patbio.2014.05.010
26. Brissot E, Alsuliman T, Gruson B, Hermet E, Tirefort Y, Yakoub-Agha I et al. [How I manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: a report of the SFGM-TC (update)]. Bull Cancer. 2017. 10.1016/j.bulcan.2017.10.022
27. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–8
28. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179–84
29. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36:749–58.10.1086/367836
30. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90:2502–8
31. Prichard MN, Britt WJ, Daily SL, Hartline CB, Kern ER. Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol. 2005;79:15494–502.10.1128/jvi.79.24.15494-15502.2005
32. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159–64
33. Cesaro S, Hirsch HH, Faraci M, Owoc-Lempach J, Beltrame A, Tendas A. et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis. 2009;49:233–40.10.1086/599829
34. Philippe M, Ranchon F, Gilis L, Schwiertz V, Vantard N, Ader F. et al. Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:723–30.10.1016/j.bbmt.2015.12.009
35. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2009;27:770–81.10.1200/jco.2008.16.8450
36. Reddy N, Goodman S, Savani BN. Prophylactic intravenous immunoglobulin does not have a role in hematopoietic stem-cell transplantation: is the evidence clear?. J Clin Oncol. 2009;27:2296–7.10.1200/jco.2009.22.0897
37. Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867–74
38. Andreoni KA, Wang X, Huong SM, Huang ES. Human CMV-IGIV (CytoGam) neutralizes human cytomegalovirus (HCMV) infectivity and prevents intracellular signal transduction after HCMV exposure. Transplant Infect Dis. 2001;3:25–30
39. Kornberg A. Intravenous immunoglobulins in liver transplant patients: perspectives of clinical immune modulation. World J Hepatol. 2015;7:1494–508.10.4254/wjh.v7.i11.1494
40. Cremer J, Schafers HJ, Wahlers T, Fieguth HG, Milbradt H, Flik J. et al. [Hyperimmunoglobulin treatment in CMV infections following heart transplantation]. Dtsch Med Wochenschr. 1988;113:18–20.10.1055/s-2008-1067585
41. Moiseev SI, Nuiia ML, Chebotkevich VN, Gonchar VA, Abdulkadyrov KM. [Cytomegalovirus infection in bone marrow transplantation]. Ter Arkh. 2002;74:44–48
42. Mikulska M, Raiola AM, Bruzzi P, Varaldo R, Annunziata S, Lamparelli T. et al. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus. Biol Blood Marrow Transplant. 2011;18:92–99.S1083-8791(11)00234-5 [pii] 10.1016/j.bbmt.2011.05.015
43. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91:78–83
44. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am. 2010;24:319–37.S0891-5520(10)00009-7 [pii] 10.1016/j.idc.2010.01.008
45. Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P. et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant. 2013;20:46–52.S1083-8791(13)00449-7 [pii] 10.1016/j.bbmt.2013.10.003
46. Ehlert K, Groll AH, Kuehn J, Vormoor J. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide. Klin Padiatr. 2006;218:180–4.10.1055/s-2006-933412
47. Herling M, Schroder L, Awerkiew S, Chakupurakal G, Holtick U, Kaiser R. et al. Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: development of multidrug resistance in the absence of anti-viral cellular immunity. J Clin Virol. 2016;74:57–60.10.1016/j.jcv.2015.11.033